Over the past 12‑18 months the Drugs for Central Nervous System industry trends have accelerated through a mix of strategic alliances, M&A activity, and regulatory shifts. In March 2024, Roche entered a co‑development partnership with Biogen to co‑screen its CRISPR‑based library for Parkinson’s disease, unlocking shared data‑platform resources. July 2024 saw Astellas Pharma acquire Ovid Therapeutics for $1.2 billion, consolidating the rare‑disease pipeline and expanding its late‑stage assets for Huntington’s. The FDA’s February 2024 approval of Neurodex, the first oral GLP‑1 analog indicated for early‑stage Alzheimer’s, marks the first product launch targeting metabolic pathways in cognition. Meanwhile, the European Medicines Agency revised its clinical‑trial guidance in May 2024, shortening patient‑enrollment timelines for CNS trials, a change that is already shortening time‑to‑market. Consumer behavior is also shifting: digital‑therapeutic platforms for anxiety saw a 38 % uptake increase, prompting pharma firms to embed tele‑health modules in their product bundles. Finally, a $560 million Series B round led by Sequoia Capital enabled NeuroBridge to expand its AI‑driven biomarker discovery hub in Dublin, adding 150 R&D staff by Q4 2024.
